| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Nullscript does not have a specific therapeutic target but is used as a negative control for the HDAC inhibitor Scriptaid. It is an inactive analog of Scriptaid that lacks the HDAC inhibitory effects. The compound may interact with other cellular targets, as it suppresses the growth of Cryptosporidium parvum with an IC50 of 2.1 µM. Its mechanism of action against Cryptosporidium is not fully characterized.
|
|---|---|
| ln Vitro |
Nullscript is an inactive analog of Scriptaid, a representative HDAC inhibitor, and is used as a negative control in experiments involving Scriptaid. It suppresses the growth of Cryptosporidium parvum with an IC50 of 2.1 µM. The compound has an optimal concentration of 6-8 µM in cell-based assay systems. Nullscript is used to distinguish HDAC-dependent effects from off-target effects of Scriptaid.
|
| ln Vivo |
In vivo activity data for Nullscript are not extensively documented. As a negative control compound for Scriptaid, it is not intended for therapeutic applications. The compound's activity against Cryptosporidium parvum suggests potential antiparasitic activity, but specific in vivo efficacy studies are not specified in the public domain. The compound is intended for research use only.
|
| Enzyme Assay |
The in vitro assay for Nullscript typically involves its use as a negative control in HDAC inhibition studies. Cells are treated with Nullscript at concentrations comparable to Scriptaid (typically 1-10 µM) to control for non-HDAC-related effects. HDAC activity is measured using fluorogenic substrates or by assessing histone acetylation by Western blot. For antiparasitic activity, Cryptosporidium parvum is incubated with varying concentrations of Nullscript, and growth inhibition is measured.
|
| Cell Assay |
In vitro cellular assays for Nullscript typically involve treating cells with the compound at concentrations ranging from 1 to 10 µM for 24-72 hours. Cellular effects are compared to those of Scriptaid to identify HDAC-dependent versus HDAC-independent effects. Cell viability is assessed using MTT or CellTiter-Glo assays. Histone acetylation is assessed by Western blot. The compound is dissolved in DMSO as a stock solution and diluted in cell culture medium.
|
| Animal Protocol |
In vivo animal studies for Nullscript are not typically performed, as the compound is used as a negative control rather than a therapeutic agent. The compound may be used in animal studies as a control for Scriptaid to distinguish HDAC-dependent effects from off-target effects. Specific protocols for in vivo studies with Nullscript are not well-established in the public domain.
|
| ADME/Pharmacokinetics |
Nullscript has a molecular weight of 298.29 g/mol and formula C16H14N2O4. Purity is typically ≥95% or ≥97%. Recommended storage is long-term in a cool, dry place. The compound is soluble in DMSO and other organic solvents. Detailed PK parameters such as half-life, Cmax, AUC, and bioavailability would require experimental determination.
|
| Toxicity/Toxicokinetics |
Nullscript is intended for research use only and is not approved for human therapeutic applications. As a negative control compound, it is generally considered to have low toxicity, but appropriate safety precautions should be taken when handling. The compound's activity against Cryptosporidium parvum suggests potential antiparasitic activity, which may be relevant for toxicity assessment.
|
| References |
|
| Additional Infomation |
4-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxybutyramide is a member of the isoquinolinoid class of compounds.
Nullscript (CAS 300816-11-9) is a structurally analogous, but functionally inactive derivative of the HDAC inhibitor Scriptaid. It has a molecular weight of 298.29 g/mol and formula C16H14N2O4. Nullscript is used as a negative control in experiments involving Scriptaid and suppresses the growth of Cryptosporidium parvum with an IC50 of 2.1 µM. It is also known as 4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxybutanamide. |
| Molecular Formula |
C16H14N2O4
|
|---|---|
| Molecular Weight |
298.29336
|
| Exact Mass |
298.095
|
| CAS # |
300816-11-9
|
| PubChem CID |
3785
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.676
|
| LogP |
-0.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
449
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1N(C(=O)C=2C3=C(C=CC=C13)C=CC2)CCCC(NO)=O
|
| InChi Key |
GBPSCCPAXYTNMB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14N2O4/c19-13(17-22)8-3-9-18-15(20)11-6-1-4-10-5-2-7-12(14(10)11)16(18)21/h1-2,4-7,22H,3,8-9H2,(H,17,19)
|
| Chemical Name |
4-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxybutanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3524 mL | 16.7622 mL | 33.5244 mL | |
| 5 mM | 0.6705 mL | 3.3524 mL | 6.7049 mL | |
| 10 mM | 0.3352 mL | 1.6762 mL | 3.3524 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
